4 Results for "

BHV3000

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "BHV3000" in MCE Product Catalog:

12
12 Publications Verification
Cat. No.: HY-15498
CAS No.: 1289023-67-1
Purity:  99.94%
Synonyms: BMS-927711; BHV-3000
Target:  

CGRP Receptor

Research Areas:  

Neurological Disease

Rimegepant (BMS-927711; BHV-3000) is an orally bioavailable and blood-brain barrier permeable antagonist of CGRP and AMY1 receptors, with a pIC50 of 8.01 and a Ki of 0.027 nM for human CGRP receptors. Rimegepant antagonizes cAMP production induced by αCGRP, βCGRP and amylin at CGRP and AMY1 receptors in humans, rats and mice, as well as at rat AMY3 receptors. Rimegepant can be used in research related to migraine .
loading...
    loading...
12
12 Publications Verification
Cat. No.: HY-15498A
CAS No.: 1374024-48-2
Synonyms: BMS-927711 sulfate hydrate; BHV-3000 sulfate hydrate
Target:  

CGRP Receptor

Research Areas:  

Neurological Disease

Rimegepant (BMS-927711) sulfate hydrate is a potent, orally active, selective and competitive calcitonin gene-related peptide (CGRP) receptor antagonist with a Ki of 0.027 nM and an IC50 of 0.14 nM for hCGRP receptor. Rimegepant sulfate hydrate can be used for migraine research .
loading...
    loading...
Cat. No.: HY-15498B
CAS No.: 1642783-82-1
Synonyms: BMS-927711 hemisulfate; BHV-3000 hemisulfate
Target:  

CGRP Receptor

Research Areas:  

Neurological Disease

Rimegepant (BMS-927711) hemisulfate is a potent, orally active, selective and competitive calcitonin gene-related peptide (CGRP) receptor antagonist with a Ki of 0.027 nM and an IC50 of 0.14 nM for hCGRP receptor. Rimegepant hemisulfate can be used for migraine research .
loading...
    loading...
Cat. No.: HY-15498S
Synonyms: BMS-927711-d4; BHV-3000-d4
Rimegepant-d4 (BMS-927711-d4) is the deuterium labeled Rimegepant (HY-15498). Rimegepant (BMS-927711) is an orally bioavailable and blood-brain barrier permeable antagonist of CGRP and AMY1 receptors, with a pIC50 of 8.01 and a Ki of 0.027 nM for human CGRP receptors. Rimegepant antagonizes cAMP production induced by αCGRP, βCGRP and amylin at CGRP and AMY1 receptors in humans, rats and mice, as well as at rat AMY3 receptors. Rimegepant can be used in research related to migraine .
loading...
    loading...